Allgens(SH:688613) Xin Lang Cai Jing·2025-04-26 02:02Core Insights - The company faced significant challenges in 2024, with net profit decreasing by 123.35% and cash flow from operating activities dropping by 137.93%, indicating a need for investor attention [1] Revenue - In 2024, the company's operating revenue was 206,033,014.77 yuan, a decrease of 9.03% from 226,475,894.98 yuan in the previous year, primarily due to the implementation of centralized procurement for orthopedic artificial bone repair materials [2] - After excluding non-core business income, the adjusted operating revenue was 200,430,853.46 yuan, reflecting an 8.24% decline, further confirming the impact of centralized procurement on revenue [2] Net Profit - The company reported a net profit attributable to shareholders of -12,662,162.69 yuan in 2024, down from 54,231,840.71 yuan in 2023, marking a 123.35% decrease [3] - Contributing factors included the impact of centralized procurement, increased operational costs, rising expenses from market activities, credit impairment losses, and higher tax burdens [3] Non-Recurring Profit - The net profit after excluding non-recurring items was -28,371,119.81 yuan in 2024, compared to 25,766,199.74 yuan in 2023, representing a 210.11% decline, indicating significant challenges in core business profitability [4] Earnings Per Share - Basic earnings per share turned negative at -0.09 yuan in 2024, down from 0.41 yuan in 2023, reflecting a 121.95% decrease [5] - The diluted earnings per share, excluding non-recurring items, also saw a significant drop to -0.21 yuan from 0.19 yuan, a decline of 210.53% [6] Expenses - Sales expenses increased by 27.35% to 48,001,433.24 yuan, driven by heightened market activities and the acquisition of HumanTech Dental [7] - Management expenses decreased by 10.38% to 75,597,292.33 yuan, primarily due to reduced share-based payments [7] - Research and development expenses were 38,767,871.53 yuan, down 14.8% from the previous year, with R&D investment accounting for 18.82% of operating revenue [7] Cash Flow - The net cash flow from operating activities was -19,603,287.90 yuan, a 137.93% decrease from 51,678,545.68 yuan in the previous year, indicating declining cash generation capacity [10] - Cash flow from investment activities improved to 14,220,071.14 yuan, a significant increase from -118,079,517.17 yuan, reflecting adjustments in investment strategies [10] - Cash flow from financing activities also increased by 103.26% to 1,050,381.13 yuan, mainly due to employee stock option exercises [10] R&D Personnel - The number of R&D personnel increased to 24 from 22, accounting for 8.86% of the total workforce, with an average salary of 58.24万元 [8][9]